8-K: BriaPro Therapeutics Reports Q3 Loss, Acquires sCD80 License

BriaPro Therapeutics Corp. filed its unaudited interim financial statements for the period ended January 31, 2026, reporting increased losses and announcing the acquisition of an exclusive license for Soluble CD80 (sCD80) for cancer treatment, alongside a $3 million credit facility from BriaCell.

Summary

• Net loss for the six months ended January 31, 2026, was $(472,231), a significant increase from $(233,185) for the same period in 2025.
• Research and development expenses increased to $433,307 for the six months ended January 31, 2026, up from $130,023 in 2025.
• General and administrative expenses slightly decreased to $64,636 for the six months ended January 31, 2026, from $80,012 in 2025.
• Acquired an exclusive worldwide license to develop and commercialize Soluble CD80 (sCD80) as a biologic agent for the treatment of cancer from BriaCell Therapeutics Corp.
• BriaCell has agreed to make available a credit facility of up to $3,000,000 to fund research and development activities related to sCD80.
• Issued 23,972,589 common shares to BriaCell with an aggregate value of approximately C$1.18 million, increasing BriaCell's ownership interest in BriaPro to approximately 78%.
• Reported a negative working capital of $1,638,799 as of January 31, 2026, worsening from $1,148,492 on July 31, 2025.
• Accumulated deficit since incorporation reached $1,652,656.
• The company's ability to continue as a going concern is dependent upon its ability to attain future profitable operations and obtain necessary financing.
• Jamieson Bondarenko was appointed as Chairman to the BriaPro board on March 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with caution due to significantly increased losses, worsening negative working capital, and explicit going concern doubts, despite the strategic acquisition of sCD80 and related credit facility.

Positives

• Acquisition of an exclusive worldwide license to develop and commercialize Soluble CD80 (sCD80) for cancer treatment, expanding the intellectual property portfolio.
• BriaCell Therapeutics Corp. provided a credit facility of up to $3,000,000 to fund sCD80 research and development activities, providing crucial near-term funding.
• Appointment of Jamieson Bondarenko as Chairman of the BriaPro board, expected to provide strategic capital markets and corporate development advice.
• Positive initial assays have shown promising results for inhibition in the development of novel protein kinase C delta (PKC-delta) inhibitors.
• Designed a battery of humanized antibodies to an important molecular target in oncology, aiming to shorten development timelines.
• Pre-clinical toxicology evaluation of BP-80 (sCD80) established a wide potential safety margin, with 50 mg/kg being a safe dose in macaques compared to an estimated human effective dose of just over 50 mg.
• Drug substance for BP-80 is available, with manufacturing into drug product anticipated within a few months, potentially accelerating clinical studies.

Negatives

• Net loss for the six months ended January 31, 2026, significantly increased to $(472,231) from $(233,185) in the prior year.
• Research and development expenses more than tripled, rising to $433,307 from $130,023 for the six-month period, indicating a high burn rate.
• Negative working capital worsened to $1,638,799 as of January 31, 2026, from $1,148,492 on July 31, 2025, highlighting severe liquidity issues.
• The accumulated deficit grew to $1,652,656 since incorporation, reflecting ongoing losses.
• The company's ability to continue as a going concern is in significant doubt, dependent on future profitable operations and additional financing.
• Cash and cash equivalents remained at $1, indicating minimal operational cash flow.
• Total current liabilities increased to $1,638,800 from $1,148,493, primarily due to increased amounts owed to related parties.

Risks

• BriaPro Shares are not currently listed on any stock exchange, and there is no assurance of future listing, implying high risk and illiquidity for investors.
• Future sales or issuances of additional securities may dilute current shareholders' voting power and earnings per share.
• Limited operating history since incorporation on May 15, 2023, with no operating revenues.
• Lack of extensive clinical data to support the clinical effectiveness and safety of developmental products.
• Unproven market for product candidates, with assumptions about market existence and expansion potentially incorrect due to competition or commercial viability issues.
• Anticipated business growth will strain managerial, operational, and technical resources, with no assurance of effective management.
• Significant reliance on third parties for manufacturing, pharmaceutical development, marketing, raw materials, and clinical trial management.
• Pre-clinical studies and initial clinical trials are not necessarily predictive of future results, and favorable early results may not be repeated.
• Inability to obtain raw materials or product supply could materially impact the business.
• Must obtain additional capital to continue operations, with no assurance of adequate or reasonable financing terms, potentially leading to delays or loss of license rights.
• Highly dependent on key personnel, and the loss of their services could materially affect the business.
• Conflicts of interest may arise for directors and officers involved in competing entities, including BriaCell.
• No history of earnings or return on investment, with no assurance of future profitability or dividends.
• Existing and proposed changes in laws and regulations for public companies may increase costs and compliance burdens.
• Issuances of additional securities will result in substantial dilution of equity interests.
• No independent operating history for BriaPro Assets, with future cash flow estimates based on combined operations with BriaCell.
• Early stage development company with novel technologies that may not be efficacious or safe, requiring significant capital for R&D.
• Government regulations, permits, and licenses may impact operations, with potential for fines, penalties, and increased costs.
• Exposure to federal, state, and provincial data protection laws (e.g., HIPAA), increasing compliance costs and potential for civil/criminal sanctions.
• Data security breaches could lead to liabilities, legal costs, and reputational damage.
• Inherent risk of product liability suits as drug candidates enter clinical trials and commercialization, potentially leading to substantial liabilities.
• Third-party license risk, as intellectual property is under third-party licenses, with uncertainty regarding availability or cost of additional licenses.
• Failure to comply with intellectual property or license agreements could lead to termination of rights.
• Reliance on the Transition Services Agreement with BriaCell, with risks if the agreement is invalid, unenforceable, or terminated.
• BriaCell's significant majority shareholding (approximately 78%) allows influence over shareholder approval matters and could delay or prevent a change in control.
• Inflation has the potential to adversely affect business by increasing overall cost structure.
• Potential material weaknesses in internal accounting controls, including lack of segregation of duties and inadequate documentation.
• Government price controls and other restrictions on pricing, reimbursement, and access to drugs may affect future revenues and profitability.
• Intellectual property litigation is substantial in the biotechnology industry, with uncertain outcomes and potential for significant costs and diversion of management attention.
• Steps taken to protect intellectual property (patents, confidentiality agreements) may be inadequate against unauthorized disclosure, infringement, or misappropriation.
• Need to initiate lawsuits to protect or enforce patents and other intellectual property rights, which can be expensive and unpredictable.
• Damage resulting from claims of inadvertent use or disclosure of trade secrets by employees/contractors.
• Regulatory approval of a new drug may face competition from generic versions, potentially harming business if patent protection and data exclusivity are not maintained.
• Patent terms may be inadequate to protect competitive position for an adequate amount of time, leading to competition from generics/biosimilars.
• Operations are subject to human error, potentially resulting in significant uninsured losses.
• Difficulty in enforcing judgments and effecting service of process on directors and officers residing outside Canada.
• Litigation can be expensive, time-consuming, and create negative perceptions, even if successful.
• Insurance coverage may be subject to limits and exclusions, or may not be obtainable on acceptable terms.
• Social media platforms can spread inaccurate or adverse information, harming the business.

Future Outlook

BriaPro expects to screen several TILsRx multi-specific binding reagents for activity in vitro and in mouse models of cancer, including TILsRx reagents carrying anti-B7-H3 antibody domains. The company aims to select at least one candidate to advance into IND enabling studies, with human clinical studies for TILsRx expected to be initiated in the first half of 2027, pending funding. In parallel, BriaPro will select novel protein kinase C delta inhibitors, optimize their structures, and advance them to the candidate selection stage, with human clinical studies expected in the second half of 2026. Anti-B7-H3 antibodies are also planned for development as antibody drug conjugates (ADC), with IND enabling studies commencing when funding is available.

Management Comments

• "The Company expects to incur further losses through to the completion of the research and development of any therapy; the nature of a development stage immune-oncology company requires the raising of financial capital to support its clinical development programs and administrative costs."
• "The Company is planning to finance its operations by exploring additional sources of capital and financing, while managing its existing working capital resources."
• "BriaPro believes that by partnering with experts in the field it has a competitive advantage to develop selective and potent PKC inhibitors."
• "The TILsRx program embodies a new concept to selectively target cancer cells. It bears risks such as that true cancer-selectivity may not be achievable, but has high potential as a new, potentially first-in-class drug platform."
• "BriaPro has expanded its technology with budgetary constraints in mind, limiting activity predominantly to computational methods and in vitro experiments."
• "To further develop these assets, BriaPro anticipates raising additional funds for animal studies including efficacy experiments in mice and toxicology/pharmacokinetics studies needed for Investigational New Drug applications."

Industry Context

StockSavvy.ai notes that BriaPro operates in the highly competitive and rapidly evolving immuno-oncology and AI-driven drug discovery markets. The global cancer immunotherapy market was estimated at $115 billion in 2022, while the AI in drug discovery market is projected to reach $20.30 billion by 2030. BriaPro's strategy of leveraging AI for novel binding agents and PKC inhibitors positions it within a high-growth, high-risk sector where innovation and speed to market are critical. Its focus on quadrivalent platforms (TILsRx) and specific targets like B7-H3 aims to differentiate it from existing bi-specific T cell engagers (BiTEs) like BLINCYTO and IMDELLTRA, which are limited by available cancer cell targets.

Comparison to Industry Standards

• BriaPro's Bria-TILsRx platform is quadrivalent, aiming for enhanced specificity and potency compared to current bi-specific T cell engagers (BiTEs) like BLINCYTO (for leukemia) and IMDELLTRA (for lung cancer), which are limited by available cancer cell targets.
• Current immunotherapies (e.g., Keytruda, Opdivo, Tecentriq) block single immune checkpoints, whereas Bria-TILsRx aims to block multiple checkpoints with a single molecule for potentially greater effectiveness.
• BriaPro's PKC inhibitors are being optimized using AI, building on previous generations (e.g., rottlerin, KAM1, BP-106) that showed increasing selectivity and potency, with BP-106 achieving 1000-fold selectivity for PKC-delta over PKC-alpha.
• The sCD80 program (BP-80) has shown promising pre-clinical results in mouse models of colon cancer (CT26) and melanoma (B16F10), slowing tumor growth. Previous sCD80 forms like Davoceticept (ALPN-202) from Alpine Therapeutics and FPT155 from Five Prime Therapeutics showed early efficacy but are no longer in development, suggesting BP-80 aims to avoid their pitfalls.
• The pre-clinical toxicology of BP-80 in cynomolgus macaques established a safe dose of 50 mg/kg, indicating a wide safety margin compared to an estimated human effective dose of just over 50 mg.

Management Changes

Corporate Governance

Legal Proceedings

• The company may become party to litigation from time to time in the ordinary course of business, or claims based on negligence or vicarious liability.
• Intellectual property litigation is substantial in the biotechnology industry, and the company may need to initiate lawsuits to protect or enforce its patent rights.
• The company may be subject to claims that it or its employees/contractors have inadvertently or otherwise used or disclosed trade secrets or proprietary information of former employers.

Related Party Transactions

• As of January 31, 2026, the total balance owing to BriaCell group companies is $1,606,112 under a transition services agreement.
• For the six months ended January 31, 2026, fixed monthly services expense from BriaCell totaled $120,000.
• Direct expenses incurred by BriaCell on behalf of BriaPro totaled $365,059 for the six-month period.
• BriaPro acquired BriaCell's exclusive license to develop and commercialize Soluble CD80 (sCD80) and related assets.
• BriaCell agreed to provide a credit facility of up to $3,000,000 to BriaPro for sCD80 R&D.
• BriaPro issued 23,972,589 common shares to BriaCell (approximately C$1.18 million value) as consideration for the sCD80 license and credit facility, increasing BriaCell's ownership to approximately 78%.

Stakeholder Impact

• Shareholders face significant dilution risk from future capital raises; BriaCell's increased majority ownership (78%) gives it substantial control over corporate actions; no current market for BriaPro shares and no assurance of future listing; potential for loss of entire investment due to high risk and early stage.
• Employees/Management may experience strain on managerial, operational, and technical resources due to anticipated growth; conflicts of interest for directors/officers also involved with BriaCell.
• Creditors face increased 'Due to related parties' balance ($1,606,112 to BriaCell) and negative working capital ($1,638,799) indicates difficulty in meeting short-term obligations without further financing.
• Customers (future) may benefit from potential novel cancer therapeutics (Bria-TILsRx, PKC inhibitors, sCD80, B7-H3 antibodies) offering improved efficacy and safety profiles compared to existing treatments.
• Suppliers/Contractors face reliance on third-party suppliers for raw materials, manufacturing, and R&D services; potential for delays or termination of programs if supply issues arise.

Next Steps

• Screen several TILsRx multi-specific binding reagents for in vitro and mouse model activity.
• Select at least one TILsRx candidate to advance into IND enabling studies.
• Initiate human clinical studies for TILsRx in the first half of 2027, pending funding.
• Select novel protein kinase C delta inhibitors, optimize structures, and advance to candidate selection stage.
• Initiate human clinical studies for PKC inhibitors in the second half of 2026.
• Develop anti-B7-H3 antibodies as antibody drug conjugates (ADC), with IND enabling studies expected when funding is available.
• Complete manufacturing of BP-80 drug product within a few months.
• Open the Investigational New Drug Application (INDA) for BP-80 following drug product manufacturing.
• Commence clinical studies with BP-80.
• Raise additional funds for animal studies (efficacy, toxicology/pharmacokinetics) needed for IND applications.

Key Dates

Recommendation

BriaPro Therapeutics is an early-stage biotech company with a limited operating history, no revenues, and a significantly worsening financial position, including a substantial increase in net loss and negative working capital. The explicit "going concern" warning, coupled with complete dependence on its parent company, BriaCell, for financing, highlights severe liquidity risks. While the acquisition of the sCD80 license and the associated credit facility offer some strategic potential, the company's overall financial instability, high R&D burn rate, and the inherent risks of early-stage drug development (unproven market, reliance on third parties, uncertain clinical trial outcomes) present a highly speculative and unfavorable investment profile. The lack of a public market for BriaPro shares further exacerbates liquidity concerns for potential investors.

Keywords

immuno-oncology, biotechnology, cancer therapeutics, sCD80, Bria-TILsRx, PKC inhibitors, B7-H3 antibodies, drug discovery, pre-clinical, clinical trials, SEC filing, financial results, going concern, capital raise, intellectual property, AI drug discovery